Halia Therapeutics Expands to Abu Dhabi
Halia Therapeutics Named as 2025 Top 10 Longevity Breakthrough Award Winner
Halia Therapeutics Published in Journey of Drug Targeting
Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer’s and other neurodegenerative diseases.
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
Trial underscores IROS’s commitment to developing innovative therapies for unmet medical needs
Novel targets for managing inflammation hold the promise of greater efficacy and safety for diseases not widely viewed as inflammatory in nature.
Halia Therapeutics’ CEO, David Bearss, recently discussed the FDA’s Project Optimus in The Wall Street Journal.
Dr. Bearss will be the Chair of the “Drug Discovery for Neurodegenerative Diseases” session, on May 23.
BioTech Nation Podcast: Fighting Inflammation, and Alzheimer’s: Dr. David Bearss, President & CEO Halia Therapeutics
Presentation to be held on Tuesday, March 19, from 11:30 a.m. – 11:45 a.m. CET
This technology will support the development of Halia’s new Alzheimer’s disease drug, HT-4253, targeting a mediator of neuroinflammation called Leucine-rich repeat kinase 2 (LRRK2)